Giant-cell arteritis and polymyalgia rheumatica

Article Abstract:

Giant-cell arteritis is an immune-mediated disease characterized by granulomatous infiltrates in the wall of medium-size and large arteries. The immunopathology consists of 2 components. Excessive cytokine production (for example, of interleukin-1 and interleukin-6) induces systemic inflammation with an exuberant acute-phase response. In parallel, interferon-gamma, which is released by T cells captured in the arterial wall, activates tissue-injurious macrophages. In response to the immune injury, the artery generates hyperplasia of the intima that leads to luminal occlusion and subsequent tissue ischemia. Despite the systemic character of the disease, distinct vascular territories are preferentially affected. ON the basis of the predominant involvement, clinical subtypes can be distinguished: cranial giant-cell arteritis with ischemic complications in the eye, the face, and the central nervous system; large-vessel giant-cell arteritis with occlusions in the subclavian or axillary vessels; aortic giant-cell arteritis; giant-cell arteritis presenting as an intense systemic inflammatory syndrome with nonstenosing vasculitis; and "isolated" polymyalgia rheumatica with myalgias, systemic inflammation, and subclinical vasculitis. Temporal artery biopsy remains the diagnostic procedure of choice to detect arteritis in cranial vessels. In other vascular territories, giant-cell arteritis is most commonly diagnosed by vascular imaging. Laboratory studies characteristically document the marked elevations of nonspecific acute-phase reactants, such as C-reactive protein and erythrocyte sedimentation rate. Cytokines, such as interleukin-6, that induce the acute-phase reaction are currently being explored as more sensitive biological markers of disease activity. Corticosteroids are highly effective in suppressing systemic inflammation, but they do not eliminate the immune responses in the vessel wall. In general, the clinical outcome of giant-cell arteritis is excellent, and efforts must now concentrate on tailoring therapies to the needs of the individual patient.

Author Abstract

---

Sonography in giant-cell arteritis

Article Abstract:

The use of ultrasound to diagnose giant-cell arteritis shows promise, but the identification of biochemical and cellular indicators of the disease will more likely improve diagnostic accuracy. Giant-cell arteritis is an inflammation of blood vessels that can lead to blindness, stroke, blood clots and death. It affects as many as one in 500 older adults. Biopsy of the suspect artery is the standard, and highly predictive, diagnostic tool, but ultrasound imaging may also identify arteritis. Biochemical markers found in the blood and vessel walls may be more useful diagnostic developments.

Editorial, Duplex ultrasonography

---

Medium- and large-vessel vasculitis

Article Abstract:

The physiology, diagnosis, and treatment of medium- and large-vessel vasculitis is reviewed. Vasculitis is an inflammation of blood vessels, and it can affect small, medium, and large blood vessels. Vasculitis that affects medium and large blood vessels includes giant-cell arteritis, polymyalgia rheumatica, and Takayasu's arteritis.

Vasculitis

Similar abstracts:

• Abstracts: Enhanced proliferation of fetal rat hepatocytes in primary culture induced by ritodrine. Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon beta
• Abstracts: The proteasome -- an emerging therapeutic target in cancer. Producing penicillin. The price tag on progress - chemotherapy for colorectal cancer
• Abstracts: Statutes and regulations relating to sexual misconduct in the practice of dentistry: part I. HIPAA security regulations: protecting patients' electronic health information
• Abstracts: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial
• Abstracts: The reconfiguration of US medicine. Mechanisms for controlling costs. Electronic technology: a spark to revitalize primary care?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.